Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Pharmaceutical industry

Manchester could pay for medicines based on efficacy

Signing of the agreement between Manchester health service and the pharmaceutical industry

Source: Stephen Williams

The Greater Manchester and Pharmaceutical Industry Partnership Group will set out to improve the use and safety of medicines and use patient data to enhance the development and delivery of medicines in the Greater Manchester region

The health service in Manchester has signed a deal with the pharmaceutical industry that could lead to the authorities paying for medicines based on their efficacy. 

The agreement between the Greater Manchester Health and Social Care Partnership — which is in charge of the region’s £6bn health and social care budget — and the pharmaceutical industry, announced on 24 February 2017, will create the Greater Manchester and Pharmaceutical Industry Partnership Group.

The new organisation will set out to improve the use and safety of medicines and use patient data to enhance the development and delivery of medicines in the Greater Manchester region.

The deal allows Greater Manchester to explore ways to pay for medicines based on patient outcomes and is intended to raise the profile of Greater Manchester as a major industry destination for the development of new treatments. 

“Our ambition is to be the safest and most effective place to receive medicines in the world and this unique step will help us on that journey,” says Jon Rouse, chief officer of Greater Manchester Health and Social Care Partnership. “We want to be able to improve people’s health, get the very best value for money from our medicines budget and continue to raise Greater Manchester’s profile as a global hub for investment in research and development.” 

The Association of the British Pharmaceutical Industry, a trade association of companies in the UK producing prescription medicines, says that the partnership will help build on the success of the Salford Lung Study and develop Greater Manchester into a global hub for life sciences research, rivalling the “golden triangle” of London, Oxford and Cambridge.

The GSK-sponsored study in chronic obstructive pulmonary disease patients — results from which were first published in May 2016 harnessed the region’s integrated electronic health records, which bring together real-time patient data from GP, pharmacy and hospital settings. 

Greater Manchester became the first region in England to gain control of its healthcare spending in April 2016 and serves 2.8 million people. Each year, spending on medicines accounts for around £1bn of Greater Manchester’s £6bn health and social care budget.

 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20202393

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Signing of the agreement between Manchester health service and the pharmaceutical industry

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.